NovaBay Pharmaceuticals Inc. (NBY) Financials Nov 14, 2014, 3:59 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for NovaBay Pharmaceuticals Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 15.68M 9.75M 11.02M 6.95M 3.48M
Cost of Goods Sold (COGS) incl. D&A - 427,000 - 341,000 476,000
COGS excluding D&A - 0 - 0 162,000
Depreciation & Amortization Expense 373,000 427,000 425,000 341,000 314,000
Depreciation 373,000 427,000 425,000 341,000 314,000
Amortization of Intangibles 0 0 0 0 0
Gross Income - 9.33M - 6.61M 3M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 12.57M 13.84M 14.92M 14.92M 18.49M
Research & Development 7.34M 8.62M 9.91M 9.28M 12.46M
Other SG&A 5.23M 5.23M 5M 5.64M 6.03M
Other Operating Expense 0 0 0 0 0
Unusual Expense 0 0 732,000 (1.44M) 555,000
EBIT after Unusual Expense 0 0 (732,000) 1.44M (555,000)
Non Operating Income/Expense (36,000) 258,000 (30,000) (155,000) 1,000
Non-Operating Interest Income 0 0 - 0 0
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense 0 0 0 0 0
Gross Interest Expense 0 0 0 0 0
Interest Capitalized 0 0 0 0 0
Pretax Income 2.7M (4.26M) (5.08M) (7.03M) (16.04M)
Income Tax 7,000 50,000 2,000 2,000 2,000
Income Tax - Current Domestic 7,000 - - 2,000 2,000
Income Tax - Current Foreign 0 - - - 0
Income Tax - Deferred Domestic 0 - - 0 0
Income Tax - Deferred Foreign 0 - - - 0
Income Tax Credits 0 - - 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 2.7M (4.31M) (5.09M) (7.03M) (16.04M)
Minority Interest Expense 0 0 0 0 0
Net Income 2.7M (4.31M) (5.09M) (7.03M) (16.04M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 2.7M (4.31M) (5.09M) (7.03M) (16.04M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 2.7M (4.31M) (5.09M) (7.03M) (16.04M)
EPS (Basic) 0.12 (0.18) (0.20) (0.24) (0.42)
Basic Shares Outstanding 22.4M 23.33M 25.77M 29.45M 38.18M
EPS (Diluted) 0.12 (0.18) (0.20) (0.24) (0.42)
Diluted Shares Outstanding 23.12M 23.33M 25.77M 29.45M 38.18M
EBITDA 3.11M (4.09M) (3.9M) (7.97M) (15.17M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for NovaBay Pharmaceuticals Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 15.68M 9.75M 11.02M 6.95M 3.48M
Cost of Goods Sold (COGS) incl. D&A - 427,000 - 341,000 476,000
COGS excluding D&A - 0 - 0 162,000
Depreciation & Amortization Expense 373,000 427,000 425,000 341,000 314,000
Depreciation 373,000 427,000 425,000 341,000 314,000
Amortization of Intangibles 0 0 0 0 0
Gross Income - 9.33M - 6.61M 3M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 12.57M 13.84M 14.92M 14.92M 18.49M
Research & Development 7.34M 8.62M 9.91M 9.28M 12.46M
Other SG&A 5.23M 5.23M 5M 5.64M 6.03M
Other Operating Expense 0 0 0 0 0
Unusual Expense 0 0 732,000 (1.44M) 555,000
EBIT after Unusual Expense 0 0 (732,000) 1.44M (555,000)
Non Operating Income/Expense (36,000) 258,000 (30,000) (155,000) 1,000
Non-Operating Interest Income 0 0 - 0 0
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense 0 0 0 0 0
Gross Interest Expense 0 0 0 0 0
Interest Capitalized 0 0 0 0 0
Pretax Income 2.7M (4.26M) (5.08M) (7.03M) (16.04M)
Income Tax 7,000 50,000 2,000 2,000 2,000
Income Tax - Current Domestic 7,000 - - 2,000 2,000
Income Tax - Current Foreign 0 - - - 0
Income Tax - Deferred Domestic 0 - - 0 0
Income Tax - Deferred Foreign 0 - - - 0
Income Tax Credits 0 - - 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 2.7M (4.31M) (5.09M) (7.03M) (16.04M)
Minority Interest Expense 0 0 0 0 0
Net Income 2.7M (4.31M) (5.09M) (7.03M) (16.04M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 2.7M (4.31M) (5.09M) (7.03M) (16.04M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 2.7M (4.31M) (5.09M) (7.03M) (16.04M)
EPS (Basic) 0.12 (0.18) (0.20) (0.24) (0.42)
Basic Shares Outstanding 22.4M 23.33M 25.77M 29.45M 38.18M
EPS (Diluted) 0.12 (0.18) (0.20) (0.24) (0.42)
Diluted Shares Outstanding 23.12M 23.33M 25.77M 29.45M 38.18M
EBITDA 3.11M (4.09M) (3.9M) (7.97M) (15.17M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
